Furmonertinib
- Generic Name
- Furmonertinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于既往经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞性肺癌(NSCLC)成人患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05987826
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 96
- Registration Number
- NCT05503667
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05466149
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Changchun, Jilin, China
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 36
- Registration Number
- NCT05465343
- Locations
- 🇨🇳
Ethics Committee, Beijing, China
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT05445310
- Locations
- 🇨🇳
Peking Union Medical College Hopital, Beijing, China
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05379803
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- ArriVent BioPharma, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT05364073
- Locations
- 🇬🇧
ArriVent Investigative Site, London, United Kingdom
🇳🇱Arrivent Investigative Site, Amsterdam, Noord-Holland, Netherlands
🇨🇳Allist Investigative Site, Taiyuan, Shanxi, China
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
- Conditions
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 280
- Registration Number
- NCT05334277
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
🇨🇳Dongguan People's Hospital, Dongguan, China
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 90
- Registration Number
- NCT05165355
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05079022
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.